MedTrace Logo

Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01528163 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2017-06-14

No results posted yet for this study

Summary

In this clinical trial, the investigators want to know if cabazitaxel is more effective than methotrexate for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in palliative treatment.

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Cabazitaxel

from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.

DRUG

Methotrexate

From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Jean-Pascal Machiels, MD, PhD · Centre du Cancer, Cliniques universitaires Saint-Luc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Belgium
  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01528163 on ClinicalTrials.gov